Chimerix, Inc. (NASDAQ:CMRX) Q4 2022 Earnings Call Transcript

And then the only other point I would add on 201 in terms of indications beyond that, as Mike mentioned a few niche opportunities. We can see that while we’re totally focused on delivering on the Phase III study for this high unmet need, we have seen evidence where the drug may be able to scale in some other niche opportunities, including experience where we’ve seen a 50% monotherapy response rate that we published out previously.

Soumit Roy: Got it. That’s really helpful. And do you see €“ along the line 6 months to 9 months from now as 206 trial starts increasing enrollment rate, do you see a competing effect on the ACTION trial or are you going to restrict 206 to non-H3 K27M-mutant patients?

Mike Sherman: Yes. It’s a great question. I was about ready to make that comment to the previous question, but we’ve essentially eliminated the overlap between the two so that if there’s a patient eligible for the ACTION study, the ACTION study is how they can access ONC201. So €“ and that’s true for other ongoing both expanded access for ONC201 and for the ONC206 program. So, essentially differentiates those two, so they’re not competing and not otherwise slowing down our enrollment for the ACTION study.

Soumit Roy: Thank you so much for taking all the questions, and congratulations again.

Mike Sherman: Thank you.

Operator: This concludes the Q&A portion of the call. I would now like to turn the call back over to Mike Sherman for closing comments.

Mike Sherman: Well, thanks, everyone, for your time this morning and look forward to providing updates in the coming months. Have a good day.

Operator: This concludes today’s conference call. We thank you for your participation. You may now disconnect.